biological source
mouse
conjugate
unconjugated
antibody form
diluted ascites fluid
antibody product type
primary antibodies
clone
121SLE, monoclonal
description
For In Vitro Diagnostic Use in Select Regions (See Chart)
form
buffered aqueous solution
species reactivity
human
packaging
vial of 0.1 mL concentrate (399M-14), vial of 0.5 mL concentrate (399M-15), bottle of 1.0 mL predilute (399M-17), vial of 1.0 mL concentrate (399M-16), bottle of 7.0 mL predilute (399M-18)
manufacturer/tradename
Cell Marque®
technique(s)
immunohistochemistry (formalin-fixed, paraffin-embedded sections): 1:25-1:100
isotype
IgM
control
colon, colon carcinoma
shipped in
wet ice
storage temp.
2-8°C
visualization
cytoplasmic
General description
Carbohydrate Antigen 19-9 (CA19-9) is a sialylated Lewis A blood group antigen. It issynthesized by glycosyltransferases and has been identified as a component of gangliosides,glycoproteins, and mucins. Anti-CA19-9 reacts with epithelial cells of the normal pancreas,stomach, and colon as well as various adenocarcinomas, including pancreatic, gastric, andcolorectal adenocarcinomas.
Physical form
Solution in Tris Buffer, pH 7.3-7.7, with 1% BSA and <0.1% Sodium Azide
Preparation Note
Download the IFU specific to your product lot and formatNote: This requires a keycode which can be found on your packaging or product label.
Analysis Note
 IVD |  IVD |  IVD |  RUO |
Other Notes
CA19-9 Positive Control Slides, Product No. 399S, are available for immunohistochemistry (formalin-fixed, paraffin-embedded sections).
For Technical Service please contact: 800-665-7284 or email: service@cellmarque.com
Legal Information
Cell Marque is a registered trademark of Merck KGaA, Darmstadt, Germany
未找到合适的产品？
试试我们的产品选型工具.
存储类别
12 - Non Combustible Liquids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
监管及禁止进口产品
此项目有
Y Tabuchi et al.
Cancer, 66(7), 1529-1533 (1990-10-01)
The correlation between CA19-9 levels of portal and peripheral venous blood, and immunohistochemical variables of cancer lesions was examined in 53 gastric cancer patients and eight patients with benign diseases. Immunohistochemically, CA19-9 was found in 33 (62.5%) of 53 primary
Seric CA 19.9 levels in patients with non tumoral pathologies. Our experience in 892 cases.
G Encabo et al.
Bulletin du cancer, 73(3), 256-259 (1986-01-01)
Gatalica Z, et al.
Appl. Immunohistochem., 2(3), 205-211 (1994)
Basso D, et al.
Medical Science Research, 17, 13-14 (1989)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持